Skip to content

Hard truths. Bold Insights. Real talk.

You’re browsing the lightweight version of Radio Generation. View the full site
Radio Generation Kenya
Radio Generation Kenya

HIV

Rachel Ruto pushes coordinated response to HIV, teen pregnancies, SGBV
Health and Wellness

Rachel Ruto pushes coordinated response to HIV, teen pregnancies, SGBV

Kenya has recorded a sharp drop in new HIV infections over the past decade, with figures from the National Syndemic Diseases Control Council showing an 82% decline between 2015 and 2025. New infections fell from 77,647 in 2015 to 13,936 in 2025. Despite the progress, Rachel said young people continued to carry a large share of the HIV burden.

By
PS Oluga: Donor exit leaves Kenya with Sh72bn health funding hole
Health and Wellness

PS Oluga: Donor exit leaves Kenya with Sh72bn health funding hole

Speaking during a Radio Generation interview on Wednesday, Oluga said Kenya has for years relied heavily on bilateral and multilateral partners to finance programmes covering HIV, tuberculosis, malaria, maternal health and other services. He said donor financing had become increasingly uncertain since 2016 as traditional development partners began prioritising domestic challenges

By
Kenya secures fresh US health partnership in drive for sustainable medical services
Health and Wellness

Kenya secures fresh US health partnership in drive for sustainable medical services

Under the framework, Kenya and the United States will work together to enhance the fight against HIV, malaria, tuberculosis and emerging disease outbreaks through improved disease monitoring, stronger laboratory networks, expanded use of digital health technologies and a more dependable supply of medical commodities.

By
Twice-yearly HIV prevention shot gets green light in South Africa
Global Affairs

Twice-yearly HIV prevention shot gets green light in South Africa

The approval signals a new era for HIV prevention efforts in Africa’s most affected nation, where millions continue to live with the virus. Developed by US biopharmaceutical firm Gilead Sciences, lenacapavir was submitted for approval in March 2025 and has now been officially registered for use among HIV-negative adults and adolescents at high risk of infection.

By